This document provides information about IsaPro Supplemental Protein from Isagenix, including what it is, its benefits, who can use it, and how to take it with other Isagenix products. Specifically:
- IsaPro is a whey protein supplement derived from pasture-fed cows that supports muscle growth and maintenance. It contains 18g of protein per serving.
- Its whey protein is processed at low temperatures to keep it in its natural state and it contains additional benefits like ionic alfalfa.
- IsaPro can benefit those looking to build muscle, lose weight, or who have specific health challenges.
- It can be mixed with other Isagenix products like IsaLean
This document lists several drugs from different companies and the HEOR value proposition studies, HTA submissions, patient reported outcomes research, and regulatory work that has been conducted for each. Studies include US HCUP/Premier data, published studies in Australia and Canada, global health state utility valuations, EORTC trials, FDA/EMA submissions, and indirect economic analyses for conditions like CNS disorders, cardiovascular disease, endocrinology, oncology, rheumatology, and respiratory disease.
This document provides information about IsaPro Supplemental Protein from Isagenix, including what it is, its benefits, who can use it, and how to take it with other Isagenix products. Specifically:
- IsaPro is a whey protein supplement derived from pasture-fed cows that supports muscle growth and maintenance. It contains 18g of protein per serving.
- Its whey protein is processed at low temperatures to keep it in its natural state and it contains additional benefits like ionic alfalfa.
- IsaPro can benefit those looking to build muscle, lose weight, or who have specific health challenges.
- It can be mixed with other Isagenix products like IsaLean
This document lists several drugs from different companies and the HEOR value proposition studies, HTA submissions, patient reported outcomes research, and regulatory work that has been conducted for each. Studies include US HCUP/Premier data, published studies in Australia and Canada, global health state utility valuations, EORTC trials, FDA/EMA submissions, and indirect economic analyses for conditions like CNS disorders, cardiovascular disease, endocrinology, oncology, rheumatology, and respiratory disease.
2016-02 Toxicidades de los nuevos fármacos en cáncer renalMartín Lázaro
Este documento presenta los resultados de varios estudios sobre el tratamiento con inhibidores de TKI y mTOR en pacientes con cáncer renal. Resume los principales efectos secundarios de estos fármacos como hipertensión, fatiga, toxicidad cutánea y mucosa, e hipotiroidismo, así como estrategias para su manejo. También analiza la correlación entre algunos efectos adversos como la hipertensión y la eficacia del tratamiento.
ASCO 2014 Highlights: Breast Cancer, Prostate Cancer; AI diagnosingdianecleverley
The document summarizes several highlights from the 2014 ASCO conference:
1) The ALTTO trial showed impressive 4-year disease-free survival rates of 95-94% for different early breast cancer treatment groups including chemotherapy, hormone therapy, and their combinations.
2) A study at MD Anderson found that an AI system called Oncology Expert Advisor was able to recommend standard-of-care cancer treatments over 80% of the time based on patient cases.
3) An IOM report found that the gaps in cancer care are expanding due to a growing cancer population and shortage of oncology professionals, emphasizing the need for improved communication between doctors and patients.
4) A study found obese
HEOR and HTA for Market Access and Value PropositionsRobert Simons
This document lists drugs from various therapeutic areas and the HEOR, HTA, patient reported outcomes, quality of life, and regulatory work done for each by different companies. It includes drugs for CNS disorders, cardiovascular diseases, endocrinology, oncology, rheumatology, and respiratory disorders from companies like Janssen-Cilag, AstraZeneca, GSK, BMS, Sanofi, Eisai, and others. For each drug, it provides information on value proposition studies, HTA submissions in various countries, quality of life assessments, and regulatory submissions to agencies like the FDA and EMA.
New immune system of information security from CHINA by WooYun - CODE BLUE 2015CODE BLUE
This talk is about the introduction of Wooyun.
WooYun is a platform where security researchers report vulnerabilities and vendors give feedbacks. While WooYun follows vulnerabilities, it also provides researchers a platform for public interests, study, communication, and research.I will introduce how WooYun works and why we start this project in my presentation, also what WooYun changes in the security circle in China, and why, when, where it built, how it developed and the difficulties when developing.
This document provides an overview of vasculitis including:
1. It classifies vasculitis based on the size of blood vessels involved - large, medium, or small vessel vasculitis.
2. It describes several specific types of vasculitis like Takayasu's arteritis, Kawasaki disease, granulomatosis with polyangiitis, and IgA vasculitis.
3. Clinical manifestations, diagnosis, and treatment options for vasculitis are discussed with an emphasis on using steroids and cytotoxic drugs to treat vasculitis.
島岡要 広島大歯・免疫学授業(2012年12月4日)Leukocyte Trafficking in Health and DiseasesBostonIDI
The document summarizes recent research findings on leukocyte trafficking and integrin activation. It discusses three key areas:
1) How integrins are activated through conformational changes triggered by cytoplasmic proteins and ligand binding.
2) The multiple routes leukocytes can take to transmigrate between endothelial cells into tissues, including paracytes playing a role.
3) Potential therapeutics targeting integrins involved in tissue-specific leukocyte homing, with examples of approved drugs and risks like PML that can be mitigated through biomarkers or small molecule inhibitors.
2016-02 Toxicidades de los nuevos fármacos en cáncer renalMartín Lázaro
Este documento presenta los resultados de varios estudios sobre el tratamiento con inhibidores de TKI y mTOR en pacientes con cáncer renal. Resume los principales efectos secundarios de estos fármacos como hipertensión, fatiga, toxicidad cutánea y mucosa, e hipotiroidismo, así como estrategias para su manejo. También analiza la correlación entre algunos efectos adversos como la hipertensión y la eficacia del tratamiento.
ASCO 2014 Highlights: Breast Cancer, Prostate Cancer; AI diagnosingdianecleverley
The document summarizes several highlights from the 2014 ASCO conference:
1) The ALTTO trial showed impressive 4-year disease-free survival rates of 95-94% for different early breast cancer treatment groups including chemotherapy, hormone therapy, and their combinations.
2) A study at MD Anderson found that an AI system called Oncology Expert Advisor was able to recommend standard-of-care cancer treatments over 80% of the time based on patient cases.
3) An IOM report found that the gaps in cancer care are expanding due to a growing cancer population and shortage of oncology professionals, emphasizing the need for improved communication between doctors and patients.
4) A study found obese
HEOR and HTA for Market Access and Value PropositionsRobert Simons
This document lists drugs from various therapeutic areas and the HEOR, HTA, patient reported outcomes, quality of life, and regulatory work done for each by different companies. It includes drugs for CNS disorders, cardiovascular diseases, endocrinology, oncology, rheumatology, and respiratory disorders from companies like Janssen-Cilag, AstraZeneca, GSK, BMS, Sanofi, Eisai, and others. For each drug, it provides information on value proposition studies, HTA submissions in various countries, quality of life assessments, and regulatory submissions to agencies like the FDA and EMA.
New immune system of information security from CHINA by WooYun - CODE BLUE 2015CODE BLUE
This talk is about the introduction of Wooyun.
WooYun is a platform where security researchers report vulnerabilities and vendors give feedbacks. While WooYun follows vulnerabilities, it also provides researchers a platform for public interests, study, communication, and research.I will introduce how WooYun works and why we start this project in my presentation, also what WooYun changes in the security circle in China, and why, when, where it built, how it developed and the difficulties when developing.
This document provides an overview of vasculitis including:
1. It classifies vasculitis based on the size of blood vessels involved - large, medium, or small vessel vasculitis.
2. It describes several specific types of vasculitis like Takayasu's arteritis, Kawasaki disease, granulomatosis with polyangiitis, and IgA vasculitis.
3. Clinical manifestations, diagnosis, and treatment options for vasculitis are discussed with an emphasis on using steroids and cytotoxic drugs to treat vasculitis.
島岡要 広島大歯・免疫学授業(2012年12月4日)Leukocyte Trafficking in Health and DiseasesBostonIDI
The document summarizes recent research findings on leukocyte trafficking and integrin activation. It discusses three key areas:
1) How integrins are activated through conformational changes triggered by cytoplasmic proteins and ligand binding.
2) The multiple routes leukocytes can take to transmigrate between endothelial cells into tissues, including paracytes playing a role.
3) Potential therapeutics targeting integrins involved in tissue-specific leukocyte homing, with examples of approved drugs and risks like PML that can be mitigated through biomarkers or small molecule inhibitors.